|
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises
|
Completed
|
Inclacumab
|
3
|
GBT2104-132
|
Prince Mohammad Bin Naser Hospital, Jizan, Saudi Arabi
|
|
Nucala Effectiveness Study (NEST) in Emerging Markets
|
Completed
|
Mepolizumab
|
3
|
213475
|
King Fahad University Hospital (Al-Khobar)
|
|
Prospective, Randomized, Open label Controlled trial to evaluate the safety and efficacy of Dexmedetomidine use beyond 24 horse Compared with Midazolam in children admitted to Pediatric Intensive Care unit (PICU) at KASCH-NGHA
|
Ongoing
|
Dexmedetomidine
|
3
|
RC20/160/R
|
King Abdulaziz Medical City NG (Riyadh)
|
|
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vasoocclusive Crises
|
Ongoing
|
Inclacumab
|
3
|
GBT2104-131
|
Prince Mohammad Bin Naser Hospital, Jizan, Saudi Arabia , Qatif Central Hospital
|
|
The Efficacy of topical Povidone – Iodine rinses in the management of CoronaVirus disease 2019 (COVID-19)
|
Ongoing
|
POVIDONE IODINE
|
2
|
E-20-5656
|
King Khalid University Hospital (Riyadh)
|
|
Efficacy Of Single Dose Rituximab and Mycophenolate Versus Two Doses Rituximab in Children with Steroid Dependent and Frequent Relapsing Nephrotic Syndrome: Randomized Open-Labeled Pilot Trial
|
Ongoing
|
Rituximab / Mycophenolate
|
2
|
2020-99
|
King Faisal Specialist Hospital and Research Center (Jeddah)
|
|
A Prospective Phase II study utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients with Advanced Colorectal Cancer
|
Ongoing
|
PANITUMUMAB - cetuximab
|
2
|
RC20/170/R
|
King Abdulaziz Medical City NG (Riyadh)
|
|
Deferoxamine management protocol in COVID-19 patients
|
Ongoing
|
Deferoxamine
|
2
|
20082103
|
King Saud Medical City (Riyadh)
|
|
A global multicenter，randomized，double-blind，placebo -controlled， adaptive designed phase Ⅲ clinical trial to evaluate the efficacy， safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in adults 18 years old and above
|
Rejected
|
Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
|
3
|
CS-CTP-AD5NCOV-ⅢCo
|
King Fahad Medical City (Riyadh)
|
|
A phase III randomized clinical trial comparing post-transplant cyclophosphamide with calcineurin inhibitors as a GVHD prophylaxis to standard care of methotrexate and calcineurin inhibitors for acute leukemia incorporating patient pharmacogenomic profiling – a personalized medicine approach in allogeneic hematopoietic cell transplantation PMAT
|
Ongoing
|
CYCLOPHOSPHAMIDE (ENDOXAN)
|
3
|
1- 28/05/2019
|
KFSH & RC-R
|
